Ming-Hui Tai, PhD

Director, Health Economic and Outcome Research (HEOR)
Novartis Pharmaceuticals Corporation

Poster(s):

• (68) Healthcare resource utilization and costs in patients with multiple sclerosis treated with ofatumumab vs ocrelizumab
  Wednesday, October 29, 2025